Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects
- PMID: 2488104
- DOI: 10.1007/BF01865512
Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects
Abstract
A double-blind, crossover comparison of the pharmacokinetics and pharmacodynamics of controlled-release metoprolol (CR) 100 mg and 200 mg, metoprolol plain tablet 100 mg, metoprolol Durules 200 mg, and placebo was carried out in 10 healthy Chinese subjects. Standardized treadmill exercise tests according to the Bruce protocol were performed at a steady state of medication, before and 2, 6, 12, and 24 hours after the dose, and multiple blood samples were collected for determination of the metoprolol concentration. The plasma metoprolol levels over 24 hours were more uniform after metoprolol CR than Durules and the plain tablet. The mean peak concentrations for CR 100 mg, 200 mg, Durules, and the plain tablets were 231, 426, 790, and 1105 nmol/l, respectively. The corresponding fluctuation incides were 1.1, 1.5, 2.2, and 5.0. The effects on exercise heart rate (EHR) were investigated at steady state. Metoprolol CR produced more even reduction in EHR over 24 hours than Durules and plain tablets. All four treatments gave similar maximal reduction in EHR of about 20% at 2 hours after the dose. In conclusion, once daily metoprolol CR showed almost even blood levels and provided relatively constant levels of beta1 blockade over 24 hours in healthy Chinese subjects.
Similar articles
-
Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.Drugs. 1992 Mar;43(3):382-414. doi: 10.2165/00003495-199243030-00006. Drugs. 1992. PMID: 1374320 Review.
-
Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses.J Clin Pharmacol. 1990 Feb;30(S2):S17-27. doi: 10.1002/j.1552-4604.1990.tb03491.x. J Clin Pharmacol. 1990. PMID: 2312775 Clinical Trial.
-
A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation.J Clin Pharmacol. 1990 Feb;30(S2):S33-8. doi: 10.1002/j.1552-4604.1990.tb03493.x. J Clin Pharmacol. 1990. PMID: 2312777 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol.J Clin Pharmacol. 1990 Feb;30(S2):S39-45. doi: 10.1002/j.1552-4604.1990.tb03494.x. J Clin Pharmacol. 1990. PMID: 2312778 Clinical Trial.
-
Achieving optimal beta1-blockade with metoprolol CR/Zok.Basic Res Cardiol. 2000;95 Suppl 1:I46-51. doi: 10.1007/s003950070009. Basic Res Cardiol. 2000. PMID: 11192353 Review.
Cited by
-
Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.Drugs. 1992 Mar;43(3):382-414. doi: 10.2165/00003495-199243030-00006. Drugs. 1992. PMID: 1374320 Review.
-
Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol.Eur J Clin Pharmacol. 1994;46(3):237-42. doi: 10.1007/BF00192555. Eur J Clin Pharmacol. 1994. PMID: 8070504 Clinical Trial.
-
A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.Cardiovasc Drugs Ther. 1995 Jun;9(3):401-6. doi: 10.1007/BF00879028. Cardiovasc Drugs Ther. 1995. PMID: 8527349 Clinical Trial.
-
Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.Pharmacoeconomics. 1994 Oct;6(4):370-400. doi: 10.2165/00019053-199406040-00004. Pharmacoeconomics. 1994. PMID: 10147474 Review.
-
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.CNS Drugs. 2017 May;31(5):389-403. doi: 10.1007/s40263-017-0430-3. CNS Drugs. 2017. PMID: 28405886 Review.